Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | APAF1 | O14727 | 1/20 | 0.38 |
| ▸ | RGS12 | O14924 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 6/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6662101 | 1.00 | MEN1 (0.41) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 | |
| Trifluoroacetic Acid SCHEMBL302072 | 0.94 | MEN1 (0.37) | MEN1HSP90AA1KMT2ASMN1; SMN2FDPS | |
| Bicarbonate SCHEMBL28733245 | 0.90 | MEN1 (0.46) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 | |
| Bicarbonate SCHEMBL28939212 | 0.90 | MEN1 (0.46) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 | |
| Bicarbonate SCHEMBL23698465 | 0.88 | ABCB11 (0.44) | MEN1HSP90AA1KMT2ASMN1; SMN2 | |
| Bicarbonate SCHEMBL23698462 | 0.88 | ABCB11 (0.44) | MEN1HSP90AA1KMT2ASMN1; SMN2 | |
| Acetic Acid SCHEMBL3140598 | 0.88 | MEN1 (0.48) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 | |
| Acetic Acid SCHEMBL23004170 | 0.88 | MEN1 (0.48) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 | |
| Acetic Acid SCHEMBL21178431 | 0.88 | MEN1 (0.48) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 | |
| Bicarbonate SCHEMBL6265469 | 0.88 | MEN1 (0.44) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7847130-B2 | Ionic additive for catalysis in biphasic reaction systems | THE UNIVERSITY COURT OF THE UNIVERSITY OF ST. ANDREWS (GB) | 2010-12-07 | — | — | US | disclosed |
| US-20090318734-A1 | IONIC ADDITIVE FOR CATALYSIS IN BIPHASIC REACTION SYSTEMS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ST. ANDREWS (GB) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318734-A1 | IONIC ADDITIVE FOR CATALYSIS IN BIPHASIC REACTION SYSTEMS | WEE2, WEE1, ITK | MEN1 3807/4885HSP90AA1 3296/4885KMT2A 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.